Investor volatility plagues drug companies on new Chinese exchange.
Mitchell
Peter
P
Jing
Fu
F
D001709:Biotechnology / Q000191:economics / Q000331:legislation & jurisprudence; D002202:Capital Financing; D002681:China; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence; D033161:Government Regulation; D018973:Intellectual Property; D007449:Investments / Q000191:economics*